Objective: To determine sensitivity and specificity of a standardized recombinant cell-based indirect immunofluorescence assay (RC-IFA) for anti-Tr antibodies in comparison to a reference procedure.
Many patients with neurologic syndromes like paraneoplastic cerebellar degeneration (PCD) have autoantibodies against neural antigens in their serum and/or CSF. PCD develops either as part of a more widespread encephalomyelitis, e.g., in patients with anti-Hu antibodies, or as an isolated syndrome, e.g., in patients with anti-Yo, anti-Ri, or anti-Tr antibodies. 1 The isolated syndrome is one of the best-characterized paraneoplastic neurologic syndromes, and when subacute severe ataxia develops in an adult patient, an immediate search for an underlying neoplasm is required. 1, 2 Knowing the type of antibody can guide that search. 3 Isolated PCD is most commonly associated with ovarian cancer, breast cancer, small cell lung cancer (SCLC), or Hodgkin lymphoma (HL). 4 The association of HL with PCD was first described in 1966, 5 and subsequently antibodies against cerebellar Purkinje cells (termed anti-Tr or PCA-Tr) were identified. 6 Anti-Tr autoantibodies are characterized based on (1) their well-defined immunostaining pattern; (2) their frequent association with HL; (3) their association with a so-called "well-characterized neurological syndrome," as defined in reference 3; (4) the unambiguous identification of these antibodies in independent studies by more than one laboratory; and (5) the low frequency of these antibodies in patients without cancer. 2 Anti-Tr antibodies are defined by a specific staining pattern in cerebellar tissue that is characterized by punctate immunoreactivity in both the dendritic tree and soma of Purkinje cells but not in their axons. 7, 8 This characteristic pattern is indicative of the presence of anti-Tr antibodies. Some laboratories encourage further confirmation of the finding by epitope blocking, which is impractical in a routine diagnostic setting. 9 In order to resolve this situation, the Tr antigen has been sought since the initial description of the anti-Tr pattern. Recently, the Delta/Notch-like epidermal growth factor-related receptor (DNER) was identified as the target antigen of anti-Tr antigen by using immunoprecipitation and then mass spectrometry. 10 In the meantime, this finding was confirmed in an independent study. 11 Using deletion constructs, the main epitope of DNER was pinpointed to the extracellular domain. 10 Now that DNER has been identified as the target antigen of anti-Tr, we are able to develop a standardized recombinant cell-based indirect immunofluorescence assay (RC-IFA). 10 In the present study, we evaluate the sensitivity and specificity of such an RC-IFA using standardized dried test systems together with a large set of well-defined anti-Tr-positive sera and controls in comparison to indirect immunofluorescence assay (IFA) using cryosections of mammalian cerebellum. We show that the new DNER assay has high sensitivity and specificity and performs better than the classic IFA using dried mammalian cerebellar cryosections that is currently used in many laboratories to determine anti-Tr.
METHODS Human sera. Anonymized sera from 38 patients with PCD were sent under code to Euroimmun by centers in the Netherlands, France, Spain, Germany, and Italy for confirmatory anti-DNER testing. All sera had previously tested positive for anti-Tr in the contributing laboratories, either by conventional immunohistochemistry or by tissue-based IFA using cryosections of rat cerebellum, according to published criteria for anti-Tr staining. 8, 12 Positive results were confirmed in most cases by epitope blocking, as described. 9 Clinical information was obtained from forms filled out by the referring neurologists, telephone interviews, and review of the clinical records. 12 The majority of patients (33) were diagnosed with PCD and HL. The remaining 5 samples included 1 patient with PCD without a confirmed tumor, 1 with limbic encephalitis and HL, 1 with paraneoplastic encephalomyelitis and HL, 1 with HL only, and 1 with unknown diagnosis. Five samples from patients with cerebellar ataxia were originally included as disease controls in a study evaluating the utility of antineuronal antibody testing in neuromyelitis optica (S.J. and B.W., unpublished data); these samples were tested in an anonymized fashion. In addition, serum samples from 207 controls were tested. Controls included 66 patients with PCD with a variety of tumors but no anti-Tr antibodies: 25 with non-HL, 12 with HL, 7 with breast cancer, 6 with non-SCLC, 3 with ovarian cancer, and 13 with other tumors. Furthermore, 53 patients with HL without neurologic symptoms were enrolled, as were 46 patients with other diseases (20 rheumatoid arthritis, 10 systemic lupus erythematosus, 10 Sjögren syndrome, 4 encephalitis, 2 neuropathy) and 42 healthy individuals.
Standard protocol approvals, registrations, and patient consents. Testing was approved by the institutional review boards of the participating institutions. Informed consent was obtained from all patients whose material was used in this study.
Cloning and expression of DNER in HEK293. The cDNAs for human DNER (UNIPROT Q8NFT8), its extracellular domain (DNER[ec]: amino acids 1-640), CDR2 (Q01850), or CDR2L (Q86X02) were obtained by performing PCR on a commercially available cDNA (BioSource, Solingen, Germany, Genbank BC035009; BC017503; BC047534). The amplification products were ligated with pTriEx-1 (Merck Biosciences, Darmstadt, Germany). DNER, DNER(ec), CDR2/Yo, or CDR2L (each with C-terminal octahistidine-tags) was expressed in human HEK293 cells after ExGen500-mediated transfection (Fermentas, St. Leon-Rot, Germany) according to the manufacturer's instructions. To prepare substrates for the IFA, HEK293 cells were grown on sterile cover glasses, transfected, and allowed to express the recombinant protein for 48 hours. Cover glasses were washed with phosphate-buffered saline (PBS), fixed with either acetone or 1% (w/v) formalin for 10 minutes at room temperature, air dried, cut into millimetersized fragments (biochips), and used as substrates in IFA (see below). For selected experiments, cells were transfected in standard T-flasks and the cell culture medium was harvested after 5 days. The medium was centrifuged at 20,000 g at 4°C for 20 minutes, and the resulting supernatant was stored in aliquots at 280°C until further use.
Detection of anti-DNER antibodies by indirect immunofluorescence. IFA was conducted using slides with a mosaic of 9 biochip substrates: HEK293-DNER, HEK293-CDR2/Yo, HEK293-CDR2L, and mock-transfected HEK293, each acetone-and formalin-fixed, as well as 4 mm unfixed cryosections of monkey cerebellum (figure 1A). Each biochip mosaic was incubated with 70 mL of PBS-diluted sample at room temperature for 30 minutes, washed with PBS-Tween, and immersed in PBS-Tween for 5 minutes. In the second step, fluorescein isothiocyanate-labeled goat anti-human IgG (Euroimmun, Lübeck, Germany) was applied and incubated at room temperature for 30 minutes. Slides were washed again with a flush of PBS-Tween and then immersed in PBS-Tween for 5 minutes. Slides were embedded in PBS-buffered DABCO containing glycerol (approximately 20 mL per field) and examined by fluorescence microscopy with 460-490 nm LED excitation (EUROStar, Euroimmun). Results were evaluated by 2 independent observers with more than 10 years of professional experience. Positive and negative controls were included during each run. Samples were classified according to the fluorescence intensity of the transfected cells in direct comparison with CDR2/Yo, CRD2L2, and mock-transfected cells and control samples. A specific fluorescence of the transfected cells at a dilution of 1:10 or higher was considered positive. A staining of monkey cerebellum was scored as having an anti-Tr pattern when a distinct punctate immunoreactivity was detected in Purkinje cell dendritic tree and soma, as previously described. 7, 8 In addition, immunoreactivity against Purkinje cell cytoplasm was scored. Endpoint titers refer to the last dilution showing visible fluorescence. In competitive inhibition experiments, recombinant antigens were mixed with diluted serum sample 30 minutes prior to the IFA, as described in Stöcker et al. 13 Purification of recombinant human DNER(ec) from HEK293 cells. The extracellular domain of DNER was expressed in HEK293 cells essentially as described for the fulllength protein. The cell culture supernatant was harvested after expression for 5 days. The recombinant protein was purified by immobilized metal affinity chromatography, as described for the extracellular domains of desmoglein 1 and 3.
14 All steps were carried out at 4°C. The fractionation of DNER(ec) was monitored by Western blot using a monoclonal antibody against hexahistidine and alkaline phosphatase anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), as in reference 14. The purified antigen was characterized by SDS-PAGE using the NuPAGE system (Invitrogen, Darmstadt, Germany) according to the manufacturer's instructions, Western blot, and MALDI-ToF fingerprinting, and MALDI-ToF tandem mass spectrometry after SDS-PAGE and tryptic cleavage. 
Miscellaneous. All reagents were obtained from Merck or
Sigma-Aldrich, Heidelberg, Germany, unless otherwise specified. Protein concentrations were determined by bicinchoninic acid assay (Sigma-Aldrich). All statistical analyses were performed using MedCalc V9.6.2.0 and SigmaPlot V10.0. A p value of 0.05 was considered statistically significant.
RESULTS

Determination of anti-DNER by indirect
immunofluorescence. Prior to the testing of all sera, fixation experiments were conducted with representative, decoded, anti-Tr-positive control sera from Erasmus MC previously shown to bind to DNER. 10 These sera reacted with both acetone-and formalin-fixed DNERtransfected HEK293 cells. However, formalin-fixed cells showed lower background staining, which allowed for more reliable evaluation of low-titer sera. Accordingly, only data obtained with the formalin-fixed DNER substrate were included in the study. In contrast to DNER, the control substrates CDR2/Yo and CDR2L were expressed intracellularly and, as expected, were only detected by anti-Yopositive control sera after acetone fixation but not after treatment with nonpermeabilizing formalin. Accordingly, acetone-fixed CDR2/Yo and CDR2L cells were used for the study. Storing experiments revealed that dust-free storing of desiccated slides containing the DNER, CDR2/Yo, and CDR2L substrates and mock-transfected control cells at 220°C for up to 12 months did not affect the outcome of individual tests.
All 38 sera with anti-Tr antibodies (as previously identified by the senders according to conventional or immunofluorescence-based immunohistochemistry) were positive for anti-DNER in the DNER RC-IFA but did not react with the control substrates ( figure 1B) . Moreover, all 6 anti-Yo-positive samples reacted with CDR2/Yo-and CDR2L-expressing cells but not with those expressing DNER or with the mock-transfected HEK293 cells. Of the other 201 control sera, none reacted with the recombinant cells or cerebellum. This corresponds to a sensitivity of 100% (95% confidence interval [CI] 92.8%-100%) and a specificity of 100% (95% CI 98.7%-100%) of the recombinant cell-based assay for anti-DNER.
When testing the same sera using the commercial non-recombinant IFA using monkey cerebellar tissue sections, only 34 of the 38 sera produced the typical anti-Tr pattern on tissue (table), corresponding to a sensitivity of 89.5% (95% CI 80.6%-89.5%). The 4 discrepant sera were derived from patients with PCD and HL. All control sera were also negative for anti-Tr in the monkey tissue-based IFA (specificity 100%, 95% CI 98.7%-100%). One control serum showed a weak cytoplasmic Purkinje cell staining pattern but no anti-Tr-specific fluorescence at a 1:10 dilution.
Endpoint titers were determined in all 38 anti-DNER-positive sera on the recombinant cells and monkey cerebellum. All but 3 sera showed higher titers when the recombinant cells were used in comparison to monkey tissue (p , 0.001, Fisher exact test) (figure 2), which yielded low-titer or negative results in 20 of 38 cases. Full reproducibility was demonstrated with representative samples on the basis of 3 subsequent slide lots, and all criteria for the CE-labeling of in vitro diagnostics in norm ISO 13485 were fulfilled.
In neutralization experiments, lysates from HEK293-DNER and purified DNER(ec) abolished anti-DNER reactivities of human sera with recombinant cells and the corresponding anti-Tr reactivity on monkey cerebellum in a dose-dependent manner (figure 1C) . High-titer sera required larger amounts of antigen than low-titer sera. In contrast, similar fractions of HEK293 cells expressing CDR2/Yo, mocktransfected HEK293, and the purified extracellular domain of desmoglein 3 14 did not affect anti-DNER or the anti-Tr reactivities. DISCUSSION We report on the first well-standardized RC-IFA, which was developed to determine autoantibodies against Tr/DNER and then evaluated using samples collected in several European centers. In a blinded study of 245 sera, including a large panel of 38 sera with anti-Tr autoantibodies, the new assay yielded 100% sensitivity and specificity with respect to the serologic precharacterization that was performed at the contributing centers. In comparison to the reference procedure, which had to use the elaborate epitope blocking step as a confirmatory measure in many cases, RC-IFA proved to be easier to perform and interpret. Our results are in agreement with the initial report on the identification of DNER as the target antigen of anti-Tr antibodies 10 and a subsequent independent confirmation study 11 that used in-house RC-IFAs and significantly smaller sample cohorts.
RCA-IFA has already been shown to be a suitable method to sensitively and specifically detect other anti-neural surface autoantibodies such as anti-NMDA receptor 16 or anti-aquaporin-4. 17, 18 Likewise, although intracellularly expressed, HEK293 cells expressing CDR2/Yo or CDR2L are apparently competent substrates for detecting autoantibodies against CDR2/Yo. All in all, recombinant cell substrates complement or even improve indirect immunofluorescence for the detection of paraneoplastic antineural autoantibodies for which cryosections of mammalian cerebellum are classically used.
By specific neutralization of the autoantibody reactions with recombinant full-length DNER expressed in HEK293, on the one hand, and the antiTr pattern on cerebellum using DNER(ec), we confirmed the earlier report on the exclusive presence of relevant epitopes in the extracellular domain of DNER. 10 We also demonstrated that the recombinant DNER(ec) construct is a fully competent antigen that may help in the development of a microplate ELISA or dot/lineblot for integration with other paraneoplastic neurologic syndrome markers such as Hu, Yo, Ri, and CV2. [19] [20] [21] As a rule, adult patients with subacute-onset cerebellar ataxia should be tested for anti-DNER and the other well-characterized onconeural antibodies. Two strategies can be used to detect anti-Tr/DNER antibodies. 22 First, an immunohistochemical screening can be performed using cryosections of cerebellum and then be confirmed in anti-DNER RC-IFA when the anti-Tr staining pattern is observed or suspected. Alternatively, direct screening can be performed using the anti-DNER RC-IFA; if the results are equivocal or the clinical data are highly suggestive, an additional immunohistochemistry could be performed as well. 22 It is most preferable, however, to determine the autoantibodies by using a multiparametric approach using mosaics of tissue and recombinant cells, similar to the approach used in this study. Symptomatology-driven sets of test substrates can be assembled, and a broad spectrum of anti-neural autoantibodies can be tested for simultaneously. This allows for a faster final diagnosis of the patient.
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